-
Forensic Exam Shows Pattern in 4 Deaths of Sanofi Dengue Vaccine Recipients
biospace
January 11, 2018
Forensic examination conducted on 4 children who received a controversial dengue vaccine indicated a "pattern" that led to their deaths, the Public Attorney's Office said Wednesday.?
-
Sanofi, Regeneron beef up investment in immunotherapies
pharmatimes
January 10, 2018
Sanofi and Regeneron are boosting their investment in development programmes for the PD-1 antibody cemiplimab in oncology and dupilumab in Type 2 (tissue specific) allergic diseases.
-
Sanofi and Alynylam rejig sees global rights switch-up
pharmafile
January 09, 2018
The Sanofi-Alynylam alliance has been in place since 2014, with the latest development seeing the two companies each take their own commercialisation lead on patisiran and fitusiran, respectively.
-
Sanofi Gains Rights to Hemophilia Drug in Restructured Deal With Alnylam
biospace
January 09, 2018
Alnylam? the leading RNAi therapeutics company, and?Sanofi?announced today a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize development and commercialization of certain products for the treatment of rare genetic dis
-
2 Underappreciated Biotech Stocks to Buy in 2018
biospace
January 03, 2018
George Budwell with?The Motley Fool?defines?value stocks?as having solid fundamentals but lower valuations than their peers. Over time, these stocks tend to outperform growth stocks.
-
Sanofi, Alnylam file hATTR amyloidosis therapy in the EU
pharmatimes
December 21, 2017
Sanofi Genzyme and Alnylam Pharmaceuticals have filed marketing applications for patisiran with the European Medicines Agency
-
Sanofi/Regeneron’s ‘breakthrough’ PD-1 hits positive notes in skin cancer
fiercebiotech
December 14, 2017
It may be way back in the race for market share, but Sanofi and Regeneron touted new topline data for their midstage checkpoint inhibitor in a certain form of skin cancer this morning.
-
Sanofi sees pipeline fruition in 2018
pharmafile
December 14, 2017
In news that Sanofi will no doubt be hoping should divert attention away from the Dengvaxia scandal, the company revealed that it expects to take a number of projects to Phase 3 and to file for regulatory approval in 2018.
-
FDA approves Sanofi's Admelog
biospectrumasia
December 14, 2017
Admelog (insulin lispro injection) 100 Units/mL will be available in U.S. in vial and SoloStar pen
-
Sanofi issues US-wide recall for arthritis product, after adverse events
pharmafile
December 13, 2017
Sanofi has announced a recall of 12,380 syringes of its Synvisc-One product for the treatment of osteoarthritis, after it was noted that a particular batch was associated with unusually high levels of adverse events.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
